Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Frequently asked questions
What sector does Voyager Therapeutics, Inc (VYGR) operate in?
Voyager Therapeutics, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Voyager Therapeutics, Inc (VYGR) current stock price?
As of the latest data, Voyager Therapeutics, Inc stock price is $1.75, with a previous close of $1.74. Voyager Therapeutics, Inc gained $0.01 in the last trading session, representing a 0.57% increase.
What is Voyager Therapeutics, Inc (VYGR) current market capitalization?
Voyager Therapeutics, Inc market cap is approximately 107.83 million.
What is Voyager Therapeutics, Inc (VYGR) Earnings Per Share (EPS)?
The trailing EPS is -$1.81, and the forward EPS is -$1.28.
What is Voyager Therapeutics, Inc (VYGR) EBITDA?
Voyager Therapeutics, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -23.55 million.
Does Voyager Therapeutics, Inc (VYGR) pay dividends?
No. Voyager Therapeutics, Inc does not pay a dividend.
How did Voyager Therapeutics, Inc (VYGR) perform in its most recent earnings report?
In the last report (June 30, 2026), Voyager Therapeutics, Inc posted an EPS surprise of 27.27% and a revenue surprise of -30.64%.
When is Voyager Therapeutics, Inc (VYGR) next earnings report?
Voyager Therapeutics, Inc is expected to release its next earnings report on September 30, 2026.
What is Voyager Therapeutics, Inc (VYGR) beta (volatility) score?
Voyager Therapeutics, Inc has a beta of 1.282, suggesting it is more volatile than the market.
